Bret Bostwick cites ApoE as a model: E4 homozygotes face 10 to 20 times higher Alzheimer's risk, E2 carriers are protected, and rare ApoE mutations can prevent disease in people destined for early onset. That rare protective evidence lets investors bookend confidence before clinical trials.
Bostwick says CNS teams miscast the brain as just another organ. He lists a blood-brain barrier built as an immune fortress, motor neurons whose axons stretch from spinal cord to ankle, and neurons that express roughly 10,000 genes with heavy alternative splicing and RNA transfer between cells.
Bostwick contrasts RNAi with serendipity-discovered small molecules: programmable drugs let teams write code for a biological pathway. Because Watson-Crick base pairing in drug design gives million-to-one or better target discrimination, he argues these modalities can act upstream with specificity that was unheard of in medicine until recently.
Bostwick says Breyer is betting on an 'in vivo renaissance,' moving drug manufacturing from bioreactors into the body with mRNA. He points to what he says is Novartis's acquisition of Abigin, an mRNA-encoded CD19 T-cell engager, as an example of replacing infusion biologics with in-body production.
Bostwick says AI can help molecule design and preclinical packages, but claiming discovery is the main bottleneck misses the cost center. He notes 90% of costs and failures sit in clinical development, so he wants companies using AI to compress biomedical timelines and trials, not just generate many compounds.
Bostwick is focused on blood-brain-barrier delivery and says transferrin-receptor shuttles will only serve a small subset of brain targets. Because some cells have TfR and others do not, he is exploring CD98, LRP1, glycocalyx interactions, scavenger receptors, and paracellular routes through BBB relaxers for delivery.
Bostwick tells preclinical teams that mice are poor proxies and human genetics is more trustworthy. His advice is to chart the fastest, most agile route to first-in-human testing, treat that trial as the starting line, and prioritize biomarker and regulatory strategy over leaning on animal data.
Bostwick warns US-based biotechs today against trying to beat China on cost by simply running the same playbook. He says Breyer wants paradigm-shifting, hard-to-reproduce innovation with a learning flywheel; truly copycat strategies are unlikely to attract investment when Chinese execution is faster and cheaper.
Bostwick says Alnylam taught him that excellent science can still die without the right people and culture. He emphasizes keeping the patient at the end of the process, building a shared team vision, and composing the team as deliberately as the chemistry or potency metrics.
Bostwick is less worried that AI erodes raw cognitive skills than that clinicians become complacent when AI is repeatedly right. He wants human verification built into systems, especially clinical decision-making, so people do not simply click enter and stop checking the machine's recommendations in practice.
Bostwick says Breyer's family-office structure is an evergreen fund with no fixed fund cycle, which lets it stay with companies through long development periods. He notes great science is not always fast and sometimes takes a decade, so patient capital becomes a real strategic advantage.
Bostwick says Breyer starts with biological ground truth, demands a clean unmet-need statement, and asks explicitly why a given modality is the right tool. The firm avoids incremental improvements and backs high-risk, programmable, paradigm-shifting platforms where medicine is treated more like an information science.
